Maeve O'Meara - 26 Dec 2023 Form 4 Insider Report for Oncology Institute, Inc. (TOI)

Reporting relationship: Director
Issuer ticker: TOI
Reported as of: 26 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Dec 2023, 16:58:10 UTC
Prior SEC filing: 21 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Maeve O'Meara

Key filing fact

Maeve O'Meara filed Form 4 for Oncology Institute, Inc. (TOI) on 28 Dec 2023.

Key facts

This page summarizes Maeve O'Meara's Form 4 filing for Oncology Institute, Inc. (TOI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Dec 2023, 16:58.

Change

Previous filing in this sequence was filed on 21 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TOI transaction

Common stock

Award

Transaction value: $0
Shares: +50,000
Change %: +85%
Price: $0.000000
Shares after: 109,104
Date: 26 Dec 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date.